Levels of prostaglandins and arachidonic acid in UV-B irradiated human skin before and after topical application of benzyl-2,5-diacetoxybenzoate, a salicylic acid derivative.
Benzyl-2,5-diacetoxybenzoate (BDAB) was tested for anti-inflammatory activity on experimentally inflamed skin. Human abdominal skin was irradiated with three minimal erythema doses of UV-B (290-320nm) radiation to give a maximum erythema at 24 hours with an associated rise in PGE2 and PGF2 alpha levels measured by gas chromatography-mass spectrometry. Topical application of a 1% w/w preparation of BDAB neither decreased the evoked erythema nor diminished the rise in PGE2 and PGF2 alpha concentrations. BDAB, applied topically, was judged to be ineffectual as an anti-inflammatory agent in UV-B erythema.
D000368:Aged; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid; D015232:Dinoprostone; D004890:Erythema / Q000188:drug therapy; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D062385:Hydroxybenzoates / Q000627:therapeutic use*; D008875:Middle Aged; D011458:Prostaglandins E / Q000032:analysis*; D011460:Prostaglandins F / Q000032:analysis*; D012867:Skin / Q000032:analysis / Q000528:radiation effects*; D014466:Ultraviolet Rays
D001095:Arachidonic Acids; D062385:Hydroxybenzoates; D011458:Prostaglandins E; D011460:Prostaglandins F; D016718:Arachidonic Acid; C035379:benzyl-2,5-diacetoxybenzoate; D015232:Dinoprostone; C100006:prostaglandin F1